Navigation Links
Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
Date:9/11/2009

MONMOUTH JUNCTION, N.J., Sept. 11 /PRNewswire/ -- Signum Biosciences, Inc has been awarded a $1.6 million Small Business Innovation Research (SBIR) Phase II grant by the National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.

In 2008, NIH/NIAID awarded Signum a SBIR Phase I grant to establish this novel class of anti-inflammatories. SBIR Phase II grants enable SBIR Phase I grantees to further develop their technology and prepare it for commercialization. Signum will use the Phase II grant to fund preclinical development of Signum's lead drug candidates for rosacea. Rosacea is a common, chronic cutaneous condition afflicting millions of individuals. FDA approved treatments have yielded mixed results, often leaving patients with significant levels of facial redness. Successful pharmaceutical development of STM anti-inflammatories will provide an important additional, and potentially better, therapeutic option for people suffering from rosacea redness.

The objective of the Phase II grant is to be granted an IND and commence Phase I clinical trials. "We are proud to have been awarded this grant and to have the reviewers at the NIH validate our technology. Building on our Phase I achievements, Signum is dedicated to developing its STM anti-inflammatory platform as novel therapeutics for rosacea as well as several other dermal skin disorders", stated Maxwell Stock, President and Chief Operating Officer.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation platform. Signum is a pioneer of this new technology which modulates targets rather than just switching-them on or off. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for Alzheimer's, Parkinson's, diabetes, and several skin conditions. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates. For more information please visit the Signum website: www.signumbiosciences.com.


'/>"/>
SOURCE Signum Biosciences, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
2. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
3. Neurocrine Biosciences Presents Elagolix Data
4. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
5. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
6. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
7. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
8. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
9. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Market Research Future published a ... Devices Market is expected to reach USD 33.6 million during the ... Market Highlights ... The Global Endoscopy Devices Market has been examined as a swiftly ... there is huge demand for endoscopy device in various regions.  The ...
(Date:1/17/2017)... Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... or the "Company") (NASDAQ: ANTH ). Such investors ... by visiting the firm,s site: www.bgandg.com/anth .   ... and/or directors have violated Sections 10(b) and 20(a) of the ... ...
(Date:1/17/2017)... 17, 2017  In a letter to President-elect ... Jenkins outlines AARP,s priorities for Americans age 50 ... access to affordable health care coverage, and lowering the ... Jenkins writes to President-elect Trump that "Our nearly 38 ... on you to protect their Medicare and Social Security ...
Breaking Medicine Technology:
(Date:1/17/2017)... Elk Grove Village, IL (PRWEB) , ... January ... ... products for musicians and music enthusiasts at the National Association of Music Merchants ... California, January 19 – 22, 2017. , Etymotic’s ER•4® has long been the ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... Medical Center joined the Peoples Health network on Dec. 1, 2016. Peoples ... , “JenCare Senior Medical Center is an exciting addition to our provider network, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein Agencies, a Denver area ... professionals throughout central Colorado, is joining local nonprofit Aurora Warms The Night to ... Night organization is committed to breaking the cycle of homelessness and poverty affecting ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie Withers Agency, ... announced the latest beneficiary of their thriving community involvement program. The current campaign ... fulfilling the dreams of terminally ill patients. Donations to this worthy cause may ...
(Date:1/16/2017)... (PRWEB) , ... January 17, 2017 , ... ... Au Bon Pain, an internationally recognized leader in the fast-casual category, announces a ... such as the Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & ...
Breaking Medicine News(10 mins):